Anthony King
Cardiovascular Disease · Kalamazoo, MINPI 1194700104
Payments from drug & device makers
Across 155 payments — averaging $324.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$25K
- Novartis$17K
- E.r. Squibb & Sons, L.L.C.$4K
- Johnson & Johnson$833
- AstraZeneca$732
- Boehringer Ingelheim$670
- plus $3K from 13 others
What the payments were for
- Speaking & faculty fees$12,67566%
- Travel & lodging$1041%
- Food & beverage$6,23832%
- Education$3012%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 21 | $24,788 |
| Novartis | 38 | $17,132 |
| E.r. Squibb & Sons, L.L.C. | 23 | $3,685 |
| Johnson & Johnson | 12 | $833 |
| AstraZeneca | 8 | $732 |
| Boehringer Ingelheim | 10 | $670 |
| Abbott | 5 | $511 |
| Merck | 1 | $450 |
| Pfizer | 7 | $320 |
| Abiomed | 15 | $303 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $242 |
| Vifor Pharma, Inc. | 1 | $119 |
| Bayer | 2 | $104 |
| Amarin Pharma, Inc. | 1 | $102 |
| Alnylam Pharmaceuticals Inc. | 1 | $95 |
| Medtronic | 2 | $90 |
| Sanofi-aventis U.S. LLC | 2 | $86 |
| Actelion Pharmaceuticals US, Inc. | 1 | $82 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$50,359 in reported general payments places this provider in the 85th percentile of 760 cardiovascular disease providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 128 | $135,117 |
| EliquisApixaban | 135 | $134,611 |
| JardianceEmpagliflozin | 99 | $73,927 |
| FarxigaDapagliflozin Propanediol | 84 | $56,615 |
| Repatha SureclickEvolocumab | 25 | $15,427 |
| XareltoRivaroxaban | 14 | $12,765 |
| VerquvoVericiguat | 12 | $9,800 |
| Ranolazine ErRanolazine | 32 | $6,029 |
| Metoprolol Succinate | 143 | $3,012 |
| Bumetanide | 57 | $2,678 |
| Isosorbide Dinitrate | 22 | $2,404 |
| Eplerenone | 15 | $1,562 |
| Atorvastatin Calcium | 104 | $1,400 |
| Spironolactone | 94 | $1,119 |
| Nitroglycerin PatchNitroglycerin | 13 | $1,115 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $17,132 | $135,117128 claims |
| PfizerEliquis | $320 | $134,611135 claims |
| Boehringer IngelheimJardiance | $670 | $73,92799 claims |
| AstraZenecaFarxiga | $732 | $56,61584 claims |
| Johnson & JohnsonXarelto | $833 | $12,76514 claims |
| MerckVerquvo | $450 | $9,80012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Kalamazoo
- Stanley ChetcutiAnn Arbor$4.3M
- Sandeep KhuranaGrandville$2.3M
- Victor MolesAnn Arbor$2.1M
- Jihad MustaphaGrand Rapids$1.9M
- Marschall RungeAnn Arbor$1.8M
- Sara SaberiAnn Arbor$1.6M
- Brian OneillDetroit$1.4M
- Vallerie McLaughlinAnn Arbor$1.4M
- Ahmad MizyedYpsilanti$1M
- Waleed DoghmiMidland$968K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.